Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 3/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698490 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL14167163 | 0.84 | TSHR (0.52) | TSHRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL697221 | 0.82 | ALDH1A1 (0.50) | TSHRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL697966 | 0.82 | TSHR (0.50) | TSHRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL7282596 | 0.81 | TSHR (0.50) | TSHRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL23480567 | 0.80 | KLK7 (0.41) | ALDH1A1MEN1KMT2AKLK7EPHX2 | |
| SCHEMBL30772713 | 0.80 | TSHR (0.40) | GLATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL9130829 | 0.80 | HPGD (0.53) | TSHRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2907816 | 0.80 | HPGD (0.53) | TSHRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1604518 | 0.80 | BRD4 (0.43) | GLATSHRALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348494-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | GLA 2788/4885TSHR 4551/4885ALDH1A1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.